Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma.

doi:10.1200/JCO.19.03327

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Oct 2020

Mellinghoff Ingo K, Ellingson Benjamin M, Touat Mehdi, Maher Elizabeth, De La Fuente Macarena I, Holdhoff Matthias, Cote Gregory M, Burris Howard, Janku Filip, Young Robert J, Huang Raymond, Jiang Liewen, Choe Sung, Fan Bin, Yen Katharine, Lu Min, Bowden Chris, Steelman Lori, Pandya Shuchi S, Cloughesy Timothy F, Wen Patrick Y

Abstract excerpt

PURPOSE: Diffuse gliomas are malignant brain tumors that include lower-grade gliomas (LGGs) and glioblastomas. Transformation of low-grade glioma into a higher tumor grade is typically associated with contrast enhancement on magnetic resonance imaging. Mutations in the isocitrate dehydrogenase 1 (IDH1) gene occur in most LGGs (> 70%). Ivosidenib is an inhibitor of mutant IDH1 (mIDH1) under evaluation in patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Dose-Response Relationship, Drug

Share to Enzyme Inhibitors

Share to Glioma

Share to Glycine

Share to Isocitrate Dehydrogenase

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 32530764
DOI: 10.1200/JCO.19.03327
PMCID: PMC7527160

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma.PMID 32530764Read ↗

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.Semantic proximity Read ↗

Glioma Response to IDH Inhibition: Real-World Experience.Semantic proximity Read ↗

The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.Semantic proximity Read ↗

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaSemantic proximity Read ↗

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.Semantic proximity Read ↗

Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase-mutant Astrocytic and Oligodendroglial Tumors.Semantic proximity Read ↗

Targeting IDH1/IDH2 mutations in gliomas.Semantic proximity Read ↗

Low-grade IDH -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitorsSemantic proximity Read ↗

Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study.Semantic proximity Read ↗

Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives.Semantic proximity Read ↗

The Role of Mutant IDH Inhibitors in the Treatment of Glioma.Semantic proximity Read ↗

Ivosidenib: First Global ApprovalSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.